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DMARD’s – Disease-Modifying Anti-Rheumatic Drugs 
Patients with rheumatoid arthritis (RA) and other chronic inflammatory 
diseases are often subject to prolonged treatment with immunosuppressive 
drugs which modify the immunologic pathways involved in the 
pathogenesis of RA. 
DMARD’s – Disease-Modifying Anti-Rheumatic Drugs 
Tumor necrosis factor alpha (TNFα) is among the cytokines that play a major role in 
the inflammatory process of rheumatic diseases. 
Its inhibition leads to substantial improvement in clinical signs and symptoms in a 
majority of patients. 
 
TNFα is able to induce tumor cell apoptosis led it to be named TNF before its role in 
the inflammatory process was revealed. 
 
TNFα or rather its nuclear factor-kappa B pathway acts as an early tumor 
suppressor. 
This property led to concerns about a possibly increased risk of malignancies when 
drugs blocking TNFα will be used for long-term treatment. 
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NMSC – nonmelanoma skin cancer 
CIS – carcinoma in situ 
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Cumulative incidence of malignancy and rate of incident cancers 
IRR – incidence  rate ratio  
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Etanercept & DMARD: long-term safety and survival 
Pts with prior cancer aHR=0.877 (95% CI 0.720, 1.069, P = 0.194) 
Pts without prior cancer aHR=0.804 (95% CI 0.460, 1.403, P = 0.442) 
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Conclusions 
1. Many randomised controlled trials have been undertaken providing data on 
the short-term safety of disease-modifying antirheumatic drugs (DMARDs). 
 
2. A milestone in the management of RA has been the development of 
registries for the long-term evaluation of the safety and effectiveness of both 
sDMARDs and bDMARDs. 
 - Registries following large cohorts of real-world RA patients provide estimates of 
risk for several agents. 
 
3. The findings from clinial trials and published literature confirm the safety 
pattern of sDMARDs and bDMARDs for the treatment of RA. 
 
4. Overall, the safety of biologic and non-biologic DMARDs appears to be 
reasonable, particularly compared with the risks associated with the disease 
itself. 

